Catalyst bench trial for FIRDAPSE patents delayed from March 23 to May 18, 2026

CATALYST PHARMACEUTICALS, INC.

District of New Jersey order delays start of bench trial to May 18, 2026, originally March 23, 2026.
Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring 2032, 2034, and 2037.
Litigation is with Hetero USA, Inc. over Catalyst's proprietary drug FIRDAPSE patents.

item 8.01

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-114306

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.